Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus MPI STANNOUS DIPHOSPHONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus MPI STANNOUS DIPHOSPHONATE.
MACROTEC vs MPI STANNOUS DIPHOSPHONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
Stannous diphosphonate is a radiopharmaceutical agent that forms a complex with technetium-99m; it localizes to areas of increased bone turnover by chemisorption to hydroxyapatite crystals, thereby enabling bone scintigraphy.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
Adult: 1-4 mg administered intravenously, single dose for bone scintigraphy.
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Terminal elimination half-life: Approximately 2.5 hours for the diphosphonate component; the stannous ion is cleared more slowly. Clinically, this allows rapid bone uptake and background clearance for imaging within 2–4 hours post-injection.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Renal: >90% of the administered dose is excreted unchanged in the urine within 24 hours. Biliary/fecal: Minimal (<2%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical